Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.54), $0.07 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $172.3 million versus the consensus estimate of $161.36 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.